A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Status:
Completed

Trial end date:
2011-03-22

Target enrollment:

Participant gender:

This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability of lapatinib administered after a high or low-fat meal.

Phase 1

GlaxoSmithKline

Lapatinib